Literature DB >> 2813665

Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age.

C Haring1, U Meise, C Humpel, A Saria, W W Fleischhacker, H Hinterhuber.   

Abstract

Drug monitoring in psychiatry is of increasing interest due to compliance problems, side effects of psychoactive drugs and the search for adequate dosage. In the present study, plasma levels of clozapine, as determined by high performance liquid chromatography, were investigated in 148 patients receiving a daily dose between 12.5 and 700 mg clozapine. Regression analysis revealed a linear relationship between dose and plasma concentrations. Plasma concentrations at a given dose (level divided by dose and body weight) in male patients reached only 69.3% of the concentrations in female patients (Mann-Whitney U Test P less than 0.001). When the patients were divided into smokers and non-smokers, the corresponding plasma levels were also found to be linearly dose dependent in each of the two groups. However, the average plasma concentration at a given dose was only 81.8% in smokers, compared to non-smokers. This difference was statistically significant (variance analysis P = 0.022). Dividing female patients into smokers and non-smokers, the smokers reached nearly the same plasma levels as the non-smokers. Male smoking patients reached average plasma concentrations which were only 67.9% of those of non-smokers. This difference was statistically significant (Mann-Whitney U Test P = 0.0083). The plasma levels of the different age groups at a given dose per kg body weight were compared using the Mann-Whitney U Test. Significant differences were found between group 1 (18-26) and group 4 (45-54) (P less than 0.01) and group 2 (27-35) and group 4 (P less than 0.01) showing higher plasma levels in the older age group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2813665     DOI: 10.1007/bf00442557

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

2.  [Thin-layer chromatographic determination of plasma levels of tricyclic psychopharmacological drugs: first results on their relationship to the clinical activity of neuroleptics (author's transl)].

Authors:  U Breyer; F Petruch; H J Gaertner; B Pflug
Journal:  Arzneimittelforschung       Date:  1976

3.  Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection.

Authors:  C Haring; C Humpel; B Auer; A Saria; C Barnas; W Fleischhacker; H Hinterhuber
Journal:  J Chromatogr       Date:  1988-06-24

4.  Effects of age and cigarette smoking on propranolol disposition.

Authors:  R E Vestal; A J Wood; R A Branch; D G Shand; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

5.  Effect of cigarette smoking on phenacetin metabolism.

Authors:  E J Pantuck; K C Hsiao; A Maggio; K Nakamura; R Kuntzman; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1974-01       Impact factor: 6.875

Review 6.  The strategy and value of neuroleptic drug monitoring.

Authors:  S H Curry
Journal:  J Clin Psychopharmacol       Date:  1985-10       Impact factor: 3.153

7.  Serum concentrations of clozapine determined by nitrogen selective gas chromatography.

Authors:  R Heipertz; H Pilz; W Beckers
Journal:  Arch Toxicol       Date:  1977-08-09       Impact factor: 5.153

  7 in total
  34 in total

1.  A therapeutic interaction between cimetidine and clozapine: case study and review of the literature.

Authors:  Magdalena Watras; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

Review 2.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 3.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

4.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

5.  Effects of clozapine on CSF homovanillic acid in spasmodic torticollis.

Authors:  A Thiel; D Dressler; A Reimer; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women.

Authors:  M Fabrazzo; G Esposito; R Fusco; M Maj
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 7.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

Authors:  C Nordin; B Almé; U Bondesson
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

10.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.